Scientists have identified an orally administered drug which they found lowers cholesterol in experimental models by 70 per cent.

The research, published in the journal Cell Reports, represents a previously unrecognised strategy for managing cholesterol and may also impact cancer treatments.

After statins, the next leading class of medications for managing cholesterol are PCSK9 inhibitors, the researchers said.